| BH3-triggered structural reorganization drives the activation of proapoptotic BAX E Gavathiotis, DE Reyna, ML Davis, GH Bird, LD Walensky Molecular cell 40 (3), 481-492, 2010 | 351 | 2010 |
| Bax regulates primary necrosis through mitochondrial dynamics RS Whelan, K Konstantinidis, AC Wei, Y Chen, DE Reyna, S Jha, Y Yang, ... Proceedings of the National Academy of Sciences 109 (17), 6566-6571, 2012 | 339 | 2012 |
| An interconnected hierarchical model of cell death regulation by the BCL-2 family HC Chen, M Kanai, A Inoue-Yamauchi, HC Tu, Y Huang, D Ren, H Kim, ... Nature cell biology 17 (10), 1270-1281, 2015 | 310 | 2015 |
| Targeting mitochondrial structure sensitizes acute myeloid leukemia to venetoclax treatment X Chen, C Glytsou, H Zhou, S Narang, DE Reyna, A Lopez, ... Cancer discovery 9 (7), 890-909, 2019 | 275 | 2019 |
| Direct and selective small-molecule activation of proapoptotic BAX E Gavathiotis, DE Reyna, JA Bellairs, ES Leshchiner, LD Walensky Nature chemical biology 8 (7), 639-645, 2012 | 198 | 2012 |
| Direct activation of BAX by BTSA1 overcomes apoptosis resistance in acute myeloid leukemia DE Reyna, TP Garner, A Lopez, F Kopp, GS Choudhary, A Sridharan, ... Cancer cell 32 (4), 490-505. e10, 2017 | 159 | 2017 |
| Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer A Lopez, DE Reyna, N Gitego, F Kopp, H Zhou, MA Miranda-Roman, ... Nature communications 13 (1), 1199, 2022 | 131 | 2022 |
| Progress in targeting the BCL-2 family of proteins TP Garner, A Lopez, DE Reyna, AZ Spitz, E Gavathiotis Current Opinion in chemical biology 39, 133-142, 2017 | 120 | 2017 |
| An autoinhibited dimeric form of BAX regulates the BAX activation pathway TP Garner, DE Reyna, A Priyadarshi, HC Chen, S Li, Y Wu, YT Ganesan, ... Molecular cell 63 (3), 485-497, 2016 | 112 | 2016 |
| Small-molecule allosteric inhibitors of BAX TP Garner, D Amgalan, DE Reyna, S Li, RN Kitsis, E Gavathiotis Nature chemical biology 15 (4), 322-330, 2019 | 92 | 2019 |
| Eltrombopag directly inhibits BAX and prevents cell death AZ Spitz, E Zacharioudakis, DE Reyna, TP Garner, E Gavathiotis Nature communications 12 (1), 1134, 2021 | 45 | 2021 |
| Optimal targeting of BCL-family proteins in head and neck squamous cell carcinoma requires inhibition of both BCL-xL and MCL-1 TJ Ow, CD Fulcher, C Thomas, PÓ Broin, A López, DE Reyna, RV Smith, ... Oncotarget 10 (4), 494, 2019 | 40 | 2019 |
| Apoptosis signaling molecules as treatment targets in head and neck squamous cell carcinoma TJ Ow, C Thomas, CD Fulcher, J Chen, A López, DE Reyna, ... The Laryngoscope 130 (11), 2643-2649, 2020 | 24 | 2020 |
| Self-regulation of BAX-induced cell death DE Reyna, E Gavathiotis Oncotarget 7 (41), 66326, 2016 | 14 | 2016 |
| Liposomal permeabilization assay to study the functional interactions of the BCL-2 family DE Reyna, E Gavathiotis BCL-2 Family Proteins: Methods and Protocols, 111-119, 2019 | 5 | 2019 |
| BAX activators and uses thereof in cancer therapy E Gavathiotis, DE Reyna, F Kopp, UG Steidl US Patent 11,382,898, 2022 | 3 | 2022 |
| Pulling the BAX trigger for tumor cell death DE Reyna, E Gavathiotis Oncotarget 9 (9), 8204, 2018 | 2 | 2018 |
| Chemical and structure-guided optimization of BAX trigger site activators for cancer therapy DE Reyna, F Kopp, E Gavathiotis Cancer Research 78 (13_Supplement), 1654-1654, 2018 | 1 | 2018 |
| BAX ACTIVATORS AND USES THEREOF IN CANCER THERAPY E Gavathiotis, DE Reyna, F Kopp, U Steidl US Patent App. 18/752,081, 2025 | | 2025 |
| BAX activators and uses thereof in cancer therapy E Gavathiotis, DE Reyna, F Kopp, U Steidl US Patent 12,016,845, 2024 | | 2024 |